MINI FUTURE OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Bid/Ask 12:50:54 2024-06-10 pm EDT | After market 02:49:36 pm | |||
| 14.22 EUR | +2.01% |
|
14.07 | -1.05% |
| Current month | -15.26% | ||
| 1 month | -32.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 14.22 | +2.01% |
| 24-06-07 | 13.94 | +1.38% |
| 24-06-06 | 13.75 | -1.01% |
| 24-06-05 | 13.89 | -4.93% |
| 24-06-04 | 14.61 | -3.94% |
Delayed Quote Börse Stuttgart
Last update June 10, 2024 at 12:50 pm EDT
More quotesStatic data
| Product type | Warrant Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB9R7X |
| ISIN | DE000JB9R7X2 |
| Date issued | 2023-12-27 |
| Strike | 634.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 21.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.8 € |
|---|---|
| Lowest since issue | 13.66 € |
| Spread | 0.04 € |
| Spread % | 0.28% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Certificates
- Certificat
